Solid Tumors News

Cellectar Biosciences Receives Additional Japanese Patent for CLR 131 and CLR 125 for the Treatment of Various ... - GlobeNewswire (press release)



Cellectar Biosciences Receives Additional Japanese Patent for CLR 131 and CLR 125 for the Treatment of Various ... 
GlobeNewswire (press release)
Most significantly, the patent includes five claims for CLR 131 and CLR 125 in treating multiple solid tumor cancer types, including brain (glioma), colorectal, intestinal, ovarian, cervical, pancreatic, lung, adrenal, retinoblastoma and skin cancers ...

and more » 


Ignyta Receives European Medicines Agency Prime Designation for Entrectinib in NTRK Fusion-Positive Solid Tumors - Business Wire (press release)



Ignyta Receives European Medicines Agency Prime Designation for Entrectinib in NTRK Fusion-Positive Solid Tumors 
Business Wire (press release)
Entrectinib was previously granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) for the treatment of NTRK fusion-positive, locally advanced or metastatic solid tumors in adult and pediatric patients who have either ...

and more » 


Breakthrough therapy for blood cancer may treat solid tumors, study suggests - The San Diego Union-Tribune



The San Diego Union-Tribune
 
Breakthrough therapy for blood cancer may treat solid tumors, study suggests 
The San Diego Union-Tribune
(Visit: http://www.uctv.tv/) Dr. Carl June presents a revolutionary form of targeted immunotherapy to fight cancer, a treatment that involves genetically modifying the patient's own T lymphocytes (a type of white blood cell) to attack cancer cells. Dr ...
British Biotech Pockets Massive Series C for its CAR-T Cancer Therapies Labiotech.eu (blog)

all 3 news articles » 


Penn Seeks to Make CAR T-Cell Therapy Work in Solid Tumor Disease - OncLive



OncLive
 
Penn Seeks to Make CAR T-Cell Therapy Work in Solid Tumor Disease 
OncLive
E. John Wherry, PhD, director of the Institute for Immunology at the Perelman School of Medicine, described successful use of CAR T cells in solid tumors as a hefty challenge given the difficulty of enabling CAR T cells to penetrate and move around ...

 


EDO Announces Next Milestone for Tinostamustine (EDO-S101) as First-In-Human Solid Tumor Study Begins - PR Newswire (press release)



EDO Announces Next Milestone for Tinostamustine (EDO-S101) as First-In-Human Solid Tumor Study Begins 
PR Newswire (press release)
Mundipharma EDO GmbH (EDO) has begun a US Phase 1/2 clinical study for tinostamustine (EDO-S101) in patients with advanced solid tumors at Stanford University, Cedars Sinai Medical Center (Los Angeles) and The Mayo Clinic (Scottsdale). The news ...

and more » 


German Pharma Enters the Clinic with Solid Tumor Treatment - Labiotech.eu (blog)



Labiotech.eu (blog)
 
German Pharma Enters the Clinic with Solid Tumor Treatment 
Labiotech.eu (blog)
A Phase I study will investigate the safety and tolerability of Immatics approach to treating solid tumors. Immatics is a German biopharma based in Tuebingen, which is a leader in the field of cancer immunotherapy. It has announced today the initiation ...

 


Nivolumab/Ipilimumab Combo Active in SCLC With High Tumor Burden - OncLive



OncLive
 
Nivolumab/Ipilimumab Combo Active in SCLC With High Tumor Burden 
OncLive
CheckMate-032 is an ongoing, open-label, phase I/II trial evaluating the safety and efficacy of 3 mg/kg of nivolumab monotherapy or 1 mg/kg of nivolumab plus 3 mg/kg of ipilimumab in advanced or metastatic solid tumors. Treatment is delivered every 3 ...

 


Global Solid Tumors Drugs Market: Growth Analysis & Projection - Medgadget (blog)



Global Solid Tumors Drugs Market: Growth Analysis & Projection 
Medgadget (blog)
Global Solid Tumors Drugs Industry Report is a professional and in-depth research report on the world's major regional market conditions of the Solid Tumors Drugs industry, focusing on the main regions (North America, Europe and Asia) and the main ...

and more » 


Aeglea BioTherapeutics Announces Clinical Collaboration with ... - Nasdaq



Aeglea BioTherapeutics Announces Clinical Collaboration with ... 
Nasdaq
AUSTIN, Texas, Oct. 16, 2017-- Aeglea BioTherapeutics, Inc., a biotechnology company committed to developing enzyme-based therapeutics in the field.

and more » 


MD Anderson Cancer Center, Pfizer to Jointly Investigate Therapies for Blood Cancers, Solid Tumors - Immuno-Oncology News



Immuno-Oncology News
 
MD Anderson Cancer Center, Pfizer to Jointly Investigate Therapies for Blood Cancers, Solid Tumors 
Immuno-Oncology News
The University of Texas MD Anderson Cancer Center and pharmaceutical giant Pfizer say they'll jointly evaluate new combinations of three investigational immunotherapies and other agents to treat various solid tumors and blood cancers. The clinical ...

and more »